AMORCE-CBPMorphometric Analysis of Sputum Cytology and Biomarkers for Lung Cancer Screening in Asbestos-Exposed Workers
This study aims to evaluate the effectiveness and accuracy of morphometric analysis and biomarkers in sputum cytology for lung cancer screening in workers exposed to asbestos, comparing it to traditional methods.
low-dose CT-scan AND induced sputum sample AND blood test
Lung Diseases+4
+ Neoplasms
+ Neoplasms by Site
Screening Study
Summary
Study start date: September 1, 2012
Actual date on which the first participant was enrolled.This study focuses on workers who have been highly exposed to asbestos, a group at high risk for lung cancer. Currently, these workers undergo repeated CT-scans for medical follow-ups, which are more effective at detecting peripheral lesions but expose individuals to radiation and risk of false-positives. The study aims to explore the potential benefits of analyzing sputum using automated cytometry, either alone or combined with CT-scans, to improve lung cancer screening in this population. The study also includes an ancillary study to evaluate the potential of blood predictive biomarkers for lung cancer. Participants in this study will provide sputum samples for analysis using automated cytometry, a method that examines cells in the sputum. The study measures the sensitivity of this method for detecting lung cancer compared to conventional cytology analysis of sputum. Additionally, the study evaluates the risk of false-positives for lung cancer detection using this method in comparison to conventional cytology analysis. The ancillary study involves blood tests to assess potential predictive biomarkers for lung cancer.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.463 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Screening Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 56 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 3 locations
Le Havre Hospital
Le Havre, FranceRouen University Hospital
Rouen, France